Your email has been successfully added to our mailing list.

×
0.0304239401496259 0.0304239401496259 0.0224438902743142 0.0166783042394014 0.00548628428927678 -0.0119700748129675 0.00349127182044889 0.0214463840399002
Stock impact report

Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors

Deciphera Pharmaceuticals, Inc. (DCPH) 
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: deciphera.com/investor-relations
Company Research Source: GlobeNewswire
WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to DCC-2618, the Company’s pan-KIT and PDGFRa inhibitor, for the treatment of gastrointestinal stromal tumors (GIST).  According to the American Cancer Society, in 2015 approximately 5,000 patients were newly diagnosed with GIST in the United States and estimates for 5-year survival range from 48% to 90% depending upon the stage of the disease at diagnosis. “The EMA orphan drug designation is a key regulatory milestone that will further facilitate and accelerate our clinical development of DCC-2618 for the treatment of GIST,” said Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer. “We believe that DCC-2618, which previously received orphan drug designation for Show less Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
DCPH alerts

from News Quantified
Opt-in for
DCPH alerts

from News Quantified